Delivery Order SPE2DR25D2108-SPE2DR26F6QS4
Award Date 11/6/25
Potential Completion Date 11/7/25
Potential Value $24K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $1,906.45 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injectors on August 18, 2025. This non-competitive delivery order represents a firm fixed price transaction with a performance completion date of August 19, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $26,102.91 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on October 22, 2025, with an ultimate completion date of October 23, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used in...
- The Defense Logistics Agency awarded a delivery order valued at $26,657.11 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, non-set-aside firm fixed price delivery order is being performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a diabetes and weight management medication, consistent with AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injectors on September 3, 2025, with completion expected by September 4, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The order will be...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $30,449.94 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on October 21, 2025, with an ultimate completion date of October 22, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is being performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a tirzepatide-based medication indicated for weight management...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- The Defense Logistics Agency awarded a delivery order valued at $8,088.02 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on July 15, 2025, with completion scheduled for July 16, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a pharmaceutical product used in diabetes and weight management...
- The Defense Logistics Agency awarded a delivery order valued at $8,691.15 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a $15,525.98 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, reflecting the...
- The Defense Logistics Agency awarded a $5,918.72 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on June 2, 2025, with an ultimate completion date of June 3, 2025. This competitive, non-set-aside award was issued from AmerisourceBergen's Conshohocken, Pennsylvania location and represents a single delivery order under the company's larger contract vehicle with DLA. Zepbound (tirzepatide) is a GLP-1 receptor agonist used for weight management...